keyword
https://read.qxmd.com/read/37767649/scaly-plaques-in-a-post-hematopoeitic-stem-cell-transplant-patient
#1
JOURNAL ARTICLE
Monica Davalos-Tanaka, Regina Gonzalez-Magaña, Christian Lizette Frías-Soria, Rodolfo Rafael Rodríguez-Jurado, Carolina Palacios-López
No abstract text is available yet for this article.
2023: Pediatric Dermatology
https://read.qxmd.com/read/36585572/whole-bone-subcutaneous-transplantation-as-a-strategy-to-study-precisely-the-bone-marrow-niche
#2
JOURNAL ARTICLE
Caroline C Picoli, Patrícia Rocha Martins, Xiao Lin Casey Wong, Thamires Righi, Pedro P G Guimarães, Mauro C X Pinto, Jaime H Amorim, Vasco A C Azevedo, Silma Regina Pereira, Alexandre Kanashiro, Fabio Cardoso Cruz, Rodrigo R Resende, Akiva Mintz, Paul S Frenette, Alexander Birbrair
Hematopoietic stem cells are maintained in a specialized microenvironment, known as the 'niche', within the bone marrow. Understanding the contribution of cellular and molecular components within the bone marrow niche for the maintenance of hematopoietic stem cells is crucial for the success of therapeutic applications. So far, the roles of crucial mechanisms within the bone marrow niche have been explored in transgenic animals in which genetic modifications are ubiquitously introduced in the whole body. The lack of precise tools to explore genetic alterations exclusively within the bone marrow prevents our determination of whether the observed outcomes result from confounding effects from other organs...
December 31, 2022: Stem cell reviews and reports
https://read.qxmd.com/read/36382360/nestin-expression-in-osteocytes-following-myeloablation-and-during-bone-marrow-metastasis
#3
JOURNAL ARTICLE
Ruth-Miriam Koerber, Rebekka K Schneider, Jessica Ellen Pritchard, Lino L Teichmann, Udo Schumacher, Peter Brossart, Ines Gütgemann
Nestin is an intermediate filament protein, which was originally detected in neuroepithelial stem cells. Besides its use as a phenotypic marker of mesenchymal stem cells in the hematopoeitic stem cell niche, the functional interpretation of nestin+ cells remains elusive. We investigated the cellular expression of nestin in bone marrow trephine biopsies of MPN patients, following myeloablation at a stage of hypocellularity during early regeneration. Here, nestin is highly expressed in mature osteocytes, arteriolar endothelial and perivascular cells and small capillaries within the bone marrow space, but not in sinusoid lining cells...
November 15, 2022: British Journal of Haematology
https://read.qxmd.com/read/35067128/relationship-between-leukaemic-stem-cells-and-hematopoietic-stem-cells-and-their-clinical-application
#4
REVIEW
Samuel S Y Wang
The world is aging and with it an associated increase in malignancies. Haematological malignancies especially Acute Myeloid Leukemia (AML) are no exception to this trend. With scientific advances, development of new AML treatments has improved patient mortality. One future research interest would be Leukeamic Stem Cells (LSC). This review aims to briefly highlight main LSC characteristics and their relationship with hematopoietic stem cells. Key LSC characteristics include dysregulated apoptosis, capacity for self-renewal, genomic instability, dysregulated energetics, immune privilege and an altered tumor microenvironment...
July 2022: Leukemia & Lymphoma
https://read.qxmd.com/read/34963514/first-successful-kidney-transplantation-after-hematopoeitic-stem-cell-transplantation-in-malaysia
#5
Min Hui Tan, Wan Mohd Rasis Wan Ahmad Kamil, Mei Chih Cheng, Seow Yeing Yee, Mohamad Zaimi Abdul Wahab, Rosnawati Yahya, Sunita Bavanandan
Promising outcomes of kidney transplantation following hematopoeitic stem cell transplantation has been reported. Data from some centers have demonstrated stable graft function without long term immunosuppression. We present our experience with the first successful case in Malaysia. This is a 21-year-old man who had acute myeloid leukemia, received stem cell transplant from his younger brother 8 years prior, underwent kidney transplantation from the same donor, and had an excellent 1-year graft function post-transplant...
July 2022: Transplantation Proceedings
https://read.qxmd.com/read/34685714/sirna-nanoparticle-targeting-pd-l1-activates-tumor-immunity-and-abrogates-pancreatic-cancer-growth-in-humanized-preclinical-model
#6
JOURNAL ARTICLE
Jae Yun Jung, Hyun Jin Ryu, Seung-Hwan Lee, Dong-Young Kim, Myung Ji Kim, Eun Ji Lee, Yeon-Mi Ryu, Sang-Yeob Kim, Kyu-Pyo Kim, Eun Young Choi, Hyung Jun Ahn, Suhwan Chang
Pancreatic cancer is characterized by late detection, frequent drug resistance, and a highly metastatic nature, leading to poor prognosis. Antibody-based immunotherapy showed limited success for pancreatic cancer, partly owing to the low delivery rate of the drug into the tumor. Herein, we describe a poly(lactic-co-glycolic acid;PLGA)-based siRNA nanoparticle targeting PD-L1 (siPD-L1@PLGA). The siPD-L1@PLGA exhibited efficient knockdown of PD-L1 in cancer cells, without affecting the cell viability up to 6 mg/mL...
October 13, 2021: Cells
https://read.qxmd.com/read/34604075/salvage-therapy-with-polatuzumab-vedotin-bendamustine-and-rituximab-prior-to-allogeneic-hematopoietic-transplantation-in-patients-with-aggressive-lymphomas-relapsing-after-therapy-with-chimeric-antigen-receptor-t-cells-report-on-two-cases
#7
Kristin Gerhardt, Madlen Jentzsch, Thomas Georgi, Aleksandra Sretenović, Michael Cross, Enrica Bach, Astrid Monecke, Sabine Leiblein, Sandra Hoffmann, Milena Todorović, Jelena Bila, Osama Sabri, Sebastian Schwind, Georg-Nikolaus Franke, Uwe Platzbecker, Vladan Vučinić
Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric antigen receptor (CAR) T-cell therapy experience treatment failure and subsequently have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains a potentially curative approach for patients in this situation. Induction of a deep response prior to alloHSCT is crucial for long-term outcomes, but the optimal bridging strategy following relapse after CAR T-cell therapy has not yet been established. Polatuzumab vedotin, an antibody drug conjugate targeting CD79b, is a novel treatment option for use in combination with rituximab and bendamustine (Pola-BR) in relapsed or refractory disease...
2021: Frontiers in Oncology
https://read.qxmd.com/read/34404617/an-innovation-in-stem-cell-harvesting-heparin-use
#8
JOURNAL ARTICLE
Hacer Gozde Gul, Mehmet Ali Erkurt, Ahmet Sarici, Irfan Kuku, Emin Kaya, Ilhami Berber, Mustafa Merter, Soykan Bicim, Mustafa Ozgul
BACKGROUND AND OBJECTIVES: Stem cell transplantation is a growing treatment strategy for most malignant and non- malignant hematological diseases. Plerixafor and granulocyte colony stimulating factor (G-CSF) are usually used in mobilization regimens to increase the CD34+ cell count in the harvest. Heparin is a sulphated glycosaminoglycated polymer with 12-15 kDa mass. Heparin inhibits the CXCR4/SDF1 axis, as does plerixafor. In this study, our aim was to investigate the effect of using heparin on stem cell mobilization and harvesting...
October 2021: Transfusion and Apheresis Science
https://read.qxmd.com/read/34121669/recurrent-aplastic-anemia-with-donor-type-aplasia-a-rare-occurrence-in-the-indian-subcontinent
#9
A Majumder, S Misra, V Kumar
Donor-type aplasia (DTA) is a condition where an individual continues to be aplastic even after a successful engraftment of a hematopoeitic stem cell transplant with a majority of donor type cells in the bone marrow. This entity has been seen with varying frequency around the world, especially in Southeast Asia. However, its incidence in the Indian subcontinent remains fairly low. Here is a case of a 17-year-old child with DTA who had a 89% population of donor cells after a successful transplant and presented with recurrent severe aplastic anemia later...
2021: Journal of Postgraduate Medicine
https://read.qxmd.com/read/33860589/clinical-efficacy-of-ruxolitinib-monotherapy-and-haploidentical-hematopoeitic-stem-cell-transplantation-in-a-child-with-philadelphia-chromosome-like-relapsed-refractory-acute-lymphoblastic-leukemia
#10
Nihan Bayram, Yöntem Yaman, Kürşat Özdilli, Leyla Telhan, Serdar Nepesov, Hülya Bilgen, Murat Elli, Sude Sema Behar, Sema Anak
INTRODUCTION: (Ph-like) ALL is a subset of leukemia which has a gene expression profile similar to Ph+disease, but without the presence of BCR-ABL1 translocation. CASE DESCRIPTION: We reported an exceptional case of a child with relapsed Ph-like ALL with IKZF1 gene deletion treated with high-dose ruxolitinib as monotherapy, after multi-agent chemotherapy. He remains in continued MRD-negative leukemia remission with full donor chimerism at 12 months post-HSCT...
June 2021: Pediatric Transplantation
https://read.qxmd.com/read/33798908/lmp7-polymorphism-may-modify-the-presentation-and-clinical-impact-of-minor-histocompatibility-antigens-in-matched-related-hematopoietic-stem-cell-transplantation
#11
JOURNAL ARTICLE
Ghada I Mossallam, Raafat Abdel Fattah, Mahmoud Bokhary, Manar Moneer, Hossam K Mahmoud
Differential expression of minor histocompatibility antigens between the recipient and donor determines their disparity and can be modified by immunoproteasomes that regulate their processing and presentation. We examined the impact of HA-1 and HA-8 disparity, and immunoproteasome LMP7 polymorphism in 130 pairs. In multivariate analysis, HA-1 disparity showed a statistically significant association with an increased incidence of acute graft-versus-host disease (aGVHD) II-IV (p = 0.043, HR: 3.71, 95%CI = 1...
March 9, 2021: Cellular Immunology
https://read.qxmd.com/read/33740322/effect-of-different-conditioning-regimens-on-survival-and-engraftment-for-children-with-hemophagocytic-lymphohistiocytosis-undergoing-allogeneic-hematopoeitic-stem-cell-transplantation-a-single-institution-experience
#12
JOURNAL ARTICLE
Salah Ali, Donna A Wall, Muhammad Ali, Kuang-Yueh Chiang, Ahmed Naqvi, Sheila Weitzman, Adam Gassas, Paul Gibson, Rae Brager, Conrad V Fernandez, Bruce Crooks, Tal Schechter, Joerg Krueger
BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH), a rare hyperinflammatory immuneregulatory disorder, is a challenge in hematopoietic stem cell transplantation (HSCT) because of the high rate of mixed chimerism, relapse, and graft failure (GF) unless intensive myeloablative regimens are used. However, historically conventional myeloablative regimens (conv MA) are associated with high toxicity and mortality. PROCEDURE: We retrospectively compared transplant outcomes between three preparative regimens of varying intensities: Conv MA (n = 15), reduced-intensity conditioning (RIC, n = 12), and a treosulfan-based reduced-toxicity conditioning (RTC, n = 9)...
September 2020: Pediatric Blood & Cancer
https://read.qxmd.com/read/33193725/hematopoietic-stem-cell-transcription-factors-in-cardiovascular-pathology
#13
REVIEW
Sushmitha Duddu, Rituparna Chakrabarti, Anuran Ghosh, Praphulla Chandra Shukla
Transcription factors as multifaceted modulators of gene expression that play a central role in cell proliferation, differentiation, lineage commitment, and disease progression. They interact among themselves and create complex spatiotemporal gene regulatory networks that modulate hematopoiesis, cardiogenesis, and conditional differentiation of hematopoietic stem cells into cells of cardiovascular lineage. Additionally, bone marrow-derived stem cells potentially contribute to the cardiovascular cell population and have shown potential as a therapeutic approach to treat cardiovascular diseases...
2020: Frontiers in Genetics
https://read.qxmd.com/read/33072711/evaluation-of-the-cost-of-survivorship-care-after-allogeneic-hematopoeitic-stem-cell-transplantation-an-analysis-of-2-german-transplantation-centers
#14
JOURNAL ARTICLE
Daniel Wolff, Jelena Bardak, Matthias Edinger, Ursula Klinger-Schindler, Ernst Holler, Anita Lawitschka, Helene Schoemans, Wolfgang Herr, Nikolaus Kröger, Francis Ayuk Ayuketang
The aim of the presented study was to analyze the care expenditure for outpatients after allogeneic hematopoietic stem cell transplantation (alloHSCT) done in accordance with the national, European guidelines and the German Social Law. We performed an analysis of the National and European survivorship care guidelines and in parallel recorded the time expenditure and staff costs separated according to different occupational groups involved in outpatient care at two German transplantation centers [University Hospital Regensburg (UKR) and University Hospital Hamburg-Eppendorf (UKE)]...
2020: Frontiers in Public Health
https://read.qxmd.com/read/33058566/advances-in-preclinical-hematopoietic-stem-cell-models-and-possible-implications-for-improving-therapeutic-transplantation
#15
REVIEW
Ellen Fraint, Bianca A Ulloa, María Feliz Norberto, Kathryn S Potts, Teresa V Bowman
Hematopoietic stem cell transplantation (HSCT) is a treatment for many malignant, congenital, and acquired hematologic diseases. Some outstanding challenges in the HSCT field include the paucity of immunologically-matched donors, our inability to effectively expand hematopoeitic stem cells (HSCs) ex vivo, and the high infection risk during engraftment. Scientists are striving to develop protocols to generate, expand and maintain HSCs ex vivo, however these are not yet ready for clinical application. Given these problems, advancing our understanding of HSC specification, regulation and differentiation in preclinical models is essential to improve the therapeutic utility of HSCT...
October 15, 2020: Stem Cells Translational Medicine
https://read.qxmd.com/read/31493540/simple-approach-to-increase-donor-hematopoietic-stem-cell-dose-and-improve-engraftment-in-the-murine-model-of-allogeneic-in-utero-hematopoietic-cell-transplantation
#16
JOURNAL ARTICLE
Jesse D Vrecenak, Emily A Partridge, Erik G Pearson, Alan W Flake
The rationale for in utero hematopoietic cell transplantation (IUHCT) rests on exploitation of normal events during hematopoietic and immunologic ontogeny to allow allogeneic hematopoietic engraftment without myeloablative conditioning.  Host hematopoietic competition is among the primary barriers to engraftment in IUHCT. In the murine model this can be partially overcome by delivery of larger donor cell doses, but volume is limiting. Enrichment of donor hematopoietic stem cells (HSCs) would seem to offer a more efficient approach, but such enriched populations have engrafted poorly in existing models of IUHCT...
September 5, 2019: Biology of Blood and Marrow Transplantation
https://read.qxmd.com/read/31467334/blocked-o-glcnac-cycling-disrupts-mouse-hematopoeitic-stem-cell-maintenance-and-early-t-cell-development
#17
JOURNAL ARTICLE
Lara K Abramowitz, Christelle Harly, Arundhoti Das, Avinash Bhandoola, John A Hanover
Small numbers of hematopoietic stem cells (HSCs) balance self-renewal and differentiation to produce the diversity and abundance of cell types that make up the blood system. How nutrients are recruited to support this massive differentiation and proliferation process remains largely unknown. The unique metabolism of adult HSCs, which rely on glycolysis and glutaminolysis, suggests a potential role for the post-translational modification O-GlcNAc as a critical nutrient signal in these cells. Glutamine, glucose, and other metabolites drive the hexosamine biosynthetic pathway (HBP) ultimately leading to the O-GlcNAc modification of critical intracellular targets...
August 29, 2019: Scientific Reports
https://read.qxmd.com/read/30307119/clinical-proteomics-for-post-hematopoeitic-stem-cell-transplantation-outcomes
#18
REVIEW
Sophie Paczesny, Jochen Metzger
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective form of tumor immunotherapy available to date. However, while HSCT can induce beneficial graft-versus-leukemia (GVL) effect, the adverse effect of graft-versus-host disease (GVHD), which is closely linked to GVL, is the major source of morbidity and mortality following HSCT. Until recently, available diagnostic and staging tools frequently fail to identify those at higher risk of disease progression or death. Furthermore, there are shortcomings in the prediction of the need for therapeutic interventions or the response rates to different forms of therapy...
October 11, 2018: Proteomics. Clinical Applications
https://read.qxmd.com/read/30121298/two-siblings-with-prkdc-defect-who-presented-with-cutaneous-granulomas-and-review-of-the-literature
#19
JOURNAL ARTICLE
Saliha Esenboga, Can Akal, Betül Karaatmaca, Baran Erman, Sibel Dogan, Diclehan Orhan, Kaan Boztug, Deniz Ayvaz, İlhan Tezcan
V(D)J recombination, during which recognition and repair of broken DNA chains are accomplished by non-homologous end joining pathway, is a critical process in B and T cell development.Null mutations of each enzyme or protein of this pathway result in T- B- NK+ severe combined immunodeficiency whereas hypomorphic mutations result in atypical(leaky)severe combined immunodeficiency forms. We present two siblings with PRKDC (Protein Kinase, DNA-Activated, Catalytic Polypeptide) mutation who presented with granulomatous skin lesions and recurrent lung infections...
August 16, 2018: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://read.qxmd.com/read/29950247/-research-progress-on-the-role-of-pyroptosis-in-the-pathogenesis-of-myelodysplastic-syndrome-review
#20
REVIEW
Ying Lin, Qing-Ping Gao, Bai-Xin Ye
Pyroptosis is a novel type of programmed cell death, which is closely related with the pathogenesis of myelodysplastic syndromes (MDS). The recent studies showed that all of S100A9/TLR4, S100A9/CD33 and Nox/ROS signaling pathways can activate oxygen-sensitivity NLRP3 inflammasome and then induce the pyroptosis of hematopoeitic stem cells (HSC) / hematopeitic pregenitor cells (HPC), resulting in ineffective hematopoiesis in patients with MDS. Further studies on the role and molecular mechanism of pyroptosis in the pathogenesis of MDS will provide the potential opportunity for the diagnosis and treatment of MDS...
June 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
keyword
keyword
62145
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.